STAT+

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about CAR-T drugs for myeloma, CVS rebate credits, and more

Health tech Mohana Ravindranath

STAT Plus: As AI marches into medicine, investors eye security, privacy startups

Biotech Damian Garde

STAT Plus: FDA advisers back CAR-T therapies in blood cancer, despite safety concerns

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a liver-drug approval, pharma’s positive outlook, and more

Pharma Allison DeAngelis

STAT Plus: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Biotech Adam Feuerstein

STAT Plus: Madrigal wins first U.S. approval for drug to treat liver disease MASH

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more

Biotech Andrew Joseph

STAT Plus: Vertex hits speed bump in getting CRISPR sickle cell therapy covered in U.K.

Pharma Andrew Joseph

STAT Plus: AstraZeneca picks up rare disease-focused Amolyt Pharma in $1 billion deal

Insurance Rachel Cohrs

STAT Plus: Medicare couldn’t cover Wegovy for weight loss. But now that it’s also a heart drug, the door is open

Health tech Casey Ross

STAT Plus: Q&A: Amid AI frenzy in medicine, a federal regulator’s quest to create safeguards

Adam's Take Adam Feuerstein

STAT Plus: Argenx readies another blockbuster opportunity with its antibody drug

Politics John Wilkerson

STAT Plus: BIO severs ties with WuXi in the face of U.S. government concerns over China

Health Tara Bannow

STAT Plus: RaDonda Vaught, former Vanderbilt nurse who accidentally killed patient, says hospital issues contributed, too

Biotech Matthew Herper and Jason Mast

STAT Plus: Small studies offer hope CAR-T can fight an aggressive brain cancer

Health Angus Chen

STAT Plus: In large trial, Guardant Health’s blood test detects colon cancer, but less reliably at earliest or precancerous stages

Pharmalot Ed Silverman

STAT Plus: Pharma loses a key battle over a state law concerning 340B pharmacies

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Amazon delivering Zepbound, hemophilia treatments, and more

Health tech Mohana Ravindranath

STAT Plus: AI health care companies say they’ll keep humans in the loop. But what does that actually mean?

Biotech Jason Mast

STAT Plus: Hemophilia gene therapies arrived after 40 years of struggle. Where are the patients?

Hospitals Katie Palmer and Casey Ross

STAT Plus: Hospitals struggle to validate AI-generated clinical summaries. ‘It’s a bit chaotic’

Politics John Wilkerson and Sarah Owermohle

STAT Plus: Here’s what you might have missed in Biden’s budget proposal

Hospitals Jon Chesto — Boston Globe

STAT Plus: For-profit health system’s Mass. hospitals teetering on the brink of financial disaster

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a failed schizophrenia drug trial, a Pfizer cancer drug, and more

Biotech Adam Feuerstein

STAT Plus: First medicine developed to treat MASH expected to be approved soon

The War on Recovery Lev Facher

STAT Plus: New methadone rules are about to take effect. Here are 6 ways treatment could shift

Biotech Adam Feuerstein

STAT Plus: Acadia’s Nuplazid fails as treatment for schizophrenia in Phase 3 study

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Wegovy approved for heart risks, an ALS drug puzzle, and more